Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

VCNX Relative to the S&P 500

VCNX Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Vaccinex, Inc. (NASD:VCNX) seasonal charts above shows that a Buy Date of November 24 and a Sell Date of February 12 has resulted in a geometric average return of 8.96% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 81.82% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 6 years of data is available for shares of VCNX, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

To download VCNX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: VCNX